PLURI INC (PLUR) Stock Fundamental Analysis
USA - NASDAQ:PLUR - US72942G2030 - Common Stock
4.09 USD
-0.05 (-1.21%)
Taking everything into account, PLUR scores 2 out of 10 in our fundamental rating. PLUR was compared to 534 industry peers in the Biotechnology industry. PLUR may be in some trouble as it scores bad on both profitability and health. PLUR shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
PLUR had negative earnings in the past year.
In the past year PLUR has reported a negative cash flow from operations.
PLUR had negative earnings in each of the past 5 years.
PLUR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -58.38%, PLUR perfoms like the industry average, outperforming 44.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.38% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-56.03%
ROA(5y)-56.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of PLUR (48.95%) is better than 75.47% of its industry peers.
PLUR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PLUR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-13.31%
2. Health
2.1 Basic Checks
PLUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PLUR has more shares outstanding
PLUR has more shares outstanding than it did 5 years ago.
PLUR has a worse debt/assets ratio than last year.
2.2 Solvency
PLUR has an Altman-Z score of -17.76. This is a bad value and indicates that PLUR is not financially healthy and even has some risk of bankruptcy.
PLUR has a worse Altman-Z score (-17.76) than 83.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.76 |
ROIC/WACCN/A
WACC7.42%
2.3 Liquidity
PLUR has a Current Ratio of 0.68. This is a bad value and indicates that PLUR is not financially healthy enough and could expect problems in meeting its short term obligations.
PLUR has a worse Current ratio (0.68) than 91.01% of its industry peers.
A Quick Ratio of 0.68 indicates that PLUR may have some problems paying its short term obligations.
PLUR's Quick ratio of 0.68 is on the low side compared to the rest of the industry. PLUR is outperformed by 90.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.68 |
3. Growth
3.1 Past
PLUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.70%, which is quite impressive.
PLUR shows a strong growth in Revenue. In the last year, the Revenue has grown by 309.82%.
The Revenue has been growing by 63.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)26.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.23%
Revenue 1Y (TTM)309.82%
Revenue growth 3Y63.03%
Revenue growth 5YN/A
Sales Q2Q%314.58%
3.2 Future
The Earnings Per Share is expected to grow by 12.63% on average over the next years. This is quite good.
The Revenue is expected to grow by 113.54% on average over the next years. This is a very strong growth
EPS Next Y87.65%
EPS Next 2Y37.16%
EPS Next 3Y19.26%
EPS Next 5Y12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y90.39%
Revenue Next 5Y113.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PLUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLUR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PLUR's earnings are expected to grow with 19.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.16%
EPS Next 3Y19.26%
5. Dividend
5.1 Amount
No dividends for PLUR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PLUR (10/21/2025, 3:03:44 PM)
4.09
-0.05 (-1.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners19.6%
Inst Owner Change0%
Ins Owners40.66%
Ins Owner Change4.37%
Market Cap33.37M
Analysts82.86
Price Target12.24 (199.27%)
Short Float %0.53%
Short Ratio2.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-42.97%
Revenue NY rev (3m)-60.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 24.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-10.32
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.23
OCFYN/A
SpS0.16
BVpS-0.84
TBVpS-1.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.38% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.95% | ||
| FCFM | N/A |
ROA(3y)-56.03%
ROA(5y)-56.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-13.31%
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 512.03% | ||
| Cap/Sales | 121.11% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.68 | ||
| Altman-Z | -17.76 |
F-Score3
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)237.36%
Cap/Depr(5y)153.18%
Cap/Sales(3y)103.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.23%
EPS Next Y87.65%
EPS Next 2Y37.16%
EPS Next 3Y19.26%
EPS Next 5Y12.63%
Revenue 1Y (TTM)309.82%
Revenue growth 3Y63.03%
Revenue growth 5YN/A
Sales Q2Q%314.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y90.39%
Revenue Next 5Y113.54%
EBIT growth 1Y-0.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.05%
OCF growth 3YN/A
OCF growth 5YN/A